Komori
D

Delta-Fly Pharma,Inc.

4598PharmaceuticalsMicro cap
73JPY-37.1%
★ Watch (sign-up required)
Price history
¥73Latest-94.1%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

Delta-Fly Pharma specializes in the research and development of anticancer drugs and is advancing the development of novel anticancer drugs using its proprietary drug discovery method known as module drug discovery. The business operates as a single-segment pharmaceutical development company and aims to generate revenue through licensing agreements with partners, primarily in Japan while also targeting overseas markets. At present, its main sources of revenue are upfront payments, milestone payments and development support payments received under licensing agreements. The company’s business model assumes that it will generate royalty income when products are launched in the future. Module drug discovery is a method of creating novel anticancer drugs by breaking down and reassembling existing anticancer drugs. The company is advancing each development product toward clinical trials and regulatory approval. Its development pipeline includes DFP-10917, DFP-14323, DFP-11207, DFP-14927, DFP-17729 and DFP-10825, among others, and it has entered into licensing agreements with partner companies in Japan and overseas with a view to obtaining regulatory approval and commencing sales.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 14
PBR
46.31How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
215.3%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥1.0bnShare price × number of shares. The value of the entire company.
Equity ratio
-131.8%The proportion of assets funded by money that does not have to be repaid.
Operating margin
-320.3%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
0.0%The average annual growth in sales over the past three years.
PSR
3.43The number of times sales are valued. Used to assess companies that are not profitable.
What to watch next
Data cutoff and interim or primary analysis disclosures for DFP-10917 (U.S. Phase 3), including monotherapy and follow-up progress
During 2026 to the next disclosure date, depending on the progress of data analysisImpact HighLikelihood Medium
Updates on patient enrollment and safety and efficacy data for DFP-10917 in combination with venetoclax (U.S. Phase 1/2)
During 2026, with disclosures expected to continue as enrollment remains ongoingImpact MediumLikelihood Medium
Disclosures on enrollment progress at major sites and the design and progress of the primary analysis for DFP-14323 (Japan Phase 3)
During 2026 to early 2027, with updates potentially provided quarterly or annually as enrollment progressesImpact MediumLikelihood Medium
Continued enrollment in the Phase 2 portion of DFP-17729 (Japan Phase 2/3) and greater clarity on consideration of the next trial
During 2026 to 2027, with disclosures accompanying completion of the analysis and transition to the next stageImpact MediumLikelihood Low
Progress on additional funding, including the exercise of stock acquisition rights and public offerings, and comparison of research and development expenses with the plan
During 2026, given indications of continuing funding needsImpact HighLikelihood High
What to watch next
Loading
Who owns itTop holders total 25.2%
Listed holders 25.2%Everyone else 74.8%
Ejima Kiyoshi (江島 淸)6.32%
BNMY SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD3.46%
NIPPON CHEMIPHAR CO.,LTD.3.27%
宮崎 大輝2.72%
Rakuten Securities, Inc. (shared account)2.09%
宮崎 羅貴1.97%
モルガン・スタンレーＭUFJ証券株式会社1.63%
MACQUARIE BANK LIMITED DBU AC Level 6,50 Martin Place Sydney NSW 2000 Australia1.33%
2 other listed holders2.39%
Who owns it
HolderOwnership (%)
Ejima Kiyoshi (江島 淸)6.32
BNMY SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD3.46
NIPPON CHEMIPHAR CO.,LTD.3.27
宮崎 大輝2.72
Rakuten Securities, Inc. (shared account)2.09
宮崎 羅貴1.97
モルガン・スタンレーＭUFJ証券株式会社1.63
MACQUARIE BANK LIMITED DBU AC Level 6,50 Martin Place Sydney NSW 2000 Australia1.33
2 other listed holders2.39
This company's documents
Filings
Timely disclosures
Threads